Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03283670 · ClinicalTrials.gov registry record · Phase 2
Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT03283670 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 24 participants.
The verdict
NCT03283670, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of the study aims to determine whether different concentrations of nitrous oxide (N2O) have different antidepressant effects for adults with treatment-resistant major depression.
Interventions
- DRUG Nitrous Oxide 25%
- DRUG Nitrous Oxide 50%
- DRUG Placebo Gas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-11-22 |
| Est. Completion | 2020-02-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03283670
The ClinicalTrials.gov registry entry for NCT03283670 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nitrous Oxide 25% is the first listed.
NCT03283670 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03283670 about?
NCT03283670 is a clinical study titled "Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies". The purpose of the study aims to determine whether different concentrations of nitrous oxide (N2O) have different antidepressant effects for adults with treatment-resistant major depression.
What is the current status of trial NCT03283670?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2016-11-22. Estimated completion is 2020-02-18.
What interventions are being tested in trial NCT03283670?
The interventions under investigation include: Nitrous Oxide 25% (DRUG), Nitrous Oxide 50% (DRUG), Placebo Gas (DRUG).
Who is sponsoring clinical trial NCT03283670?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.